Vertex and partner CRISPR Therapeutics’ CRSP ... to offer enhanced patient benefit than Trikafta and become a new standard-of-care treatment in CF. It can potentially treat CF patients who ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.

"We have the opportunity to change the paradigm of acute pain management and establish a new standard of care," Dr. Reshma Kewalramani, Vertex CEO, said in a statement. Vertex said Journavx will ...

Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through ...